Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis
NCT02204397
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
5
Enrollment
OTHER
Sponsor class
Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG:
INGAP Peptide, Ustekinumab
Sponsor
Jewish General Hospital